• Publications
  • Influence
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
BACKGROUND Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Expand
  • 4,063
  • 157
  • PDF
Update on AUA guideline on the management of benign prostatic hyperplasia.
PURPOSE To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH). MATERIALS AND METHODS From MEDLINE® searches ofExpand
  • 819
  • 71
Early detection of prostate cancer: AUA Guideline.
PURPOSE The guideline purpose is to provide the urologist with a framework for the early detection of prostate cancer in asymptomatic average risk men. MATERIALS AND METHODS A systematic review wasExpand
  • 838
  • 34
  • PDF
Prostate Cancer, Version 1.2016.
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease.Expand
  • 463
  • 32
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
CONTEXT Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive and advanced prostate cancer, but it has also been associated with adverse effects on bone, metabolic,Expand
  • 358
  • 23
  • PDF
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study.
PURPOSE Prior studies of postoperative outcomes following radical prostatectomy have been limited by selection bias and short-term followup. In this study we assessed temporal changes in urinary andExpand
  • 518
  • 21
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.
The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advancedExpand
  • 360
  • 18
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.
PURPOSE We examined risk factors for incident symptomatic benign prostate hyperplasia in 5,667 Prostate Cancer Prevention Trial placebo arm participants who were free of benign prostatic hyperplasiaExpand
  • 186
  • 16
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study.
BACKGROUND Men treated for clinically localized prostate cancer with either radical prostatectomy or external beam radiotherapy usually survive many years with the side effects of these treatments.Expand
  • 429
  • 15
  • PDF
Castration-resistant prostate cancer: AUA Guideline.
PURPOSE This Guideline is intended to provide a rational basis for the management of patients with castration-resistant prostate cancer based on currently available published data. MATERIALS ANDExpand
  • 239
  • 12
  • PDF